Clinical trial

Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)

NCT00795899

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2002-01-01

PhasePHASE2

Study timeline

Study start (unknown)2002-01-01Date precision: month

Registry last updated2011-08-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

Epirubicin / Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative TrastuzumabDRUG

Sponsors & collaborators

GBG Forschungs GmbHlead sponsor

AGO Study Groupcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00795899 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.